Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings Patents (Class 514/33)
-
Patent number: 7854922Abstract: The present invention has an object to provide an external dermatological formulation having satisfactory blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing effect, hair nourishing effect, emusifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and/or transdermal absorption-promoting effect with a satisfactory safety and skin feeling; The object is solved by providing an external dermatological formulation comprising a saccharide derivative of ?,?-trehalose and one or more members selected from substances having any one of blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing efect, hair nourishing effect, emulsifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and transdermalType: GrantFiled: February 10, 2004Date of Patent: December 21, 2010Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Fujimi Tanabe, Michio Kubota, Hiromi Tatsukawa, Shigeharu Fukuda, Toshio Miyake
-
Publication number: 20100317606Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cType: ApplicationFiled: August 13, 2010Publication date: December 16, 2010Applicant: PACIFIC ARROW LIMITEDInventors: Pui-Kwong CHAN, May Sung MAK
-
Publication number: 20100310684Abstract: Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract containing at least one of an anthocyanoside or a proanthocyanidin for the treatment or prevention of mucositis. The therapeutically effective amount of the anthocyanoside, proanthocyanidin or extract can be administered alone or in combination with a therapeutically effective amount of at least one of an anti-inflammatory agent, immunomodulating agent, analgesic, antimicrobial agent or antifungal agent. Also disclosed herein are pharmaceutical compositions for treating and preventing mucositis.Type: ApplicationFiled: August 16, 2010Publication date: December 9, 2010Inventors: Ezio Bombardelli, Paolo Morazzoni
-
Publication number: 20100310687Abstract: The present invention relates to a Momordicae semen extract effective in the prevention and treatment of gastritis or gastric ulcer and momordica saponin I isolated therefrom. The Momordicae semen extract and the momordica saponin I isolated therefrom is effective in the prevention and treatment of gastritis or gastric ulcer since they prevent the damage of the gastric mucosa caused by alcohols and inhibit the secretion of gastric acid.Type: ApplicationFiled: August 16, 2010Publication date: December 9, 2010Applicant: SK Chemicals Co., Ltd.Inventors: Bong Cheol KIM, Joo Hyon Kim, Se Jun Yun, Eun Jung Noh, Gi Uk Jang, Chang-Kyun Han, Yong-Baik Cho, Wie-Jong Kwak
-
Publication number: 20100310487Abstract: An active ingredient combination which comprises a) glycerol monoalkyl ether, b) bispyridinium alkane, c) polyol and d) antioxidant. The combination is advantageously used for producing a preparation for the treatment of undesired body odour, for example for producing a cosmetic deodorant preparation, an antidandruff hair cleansing composition, a preparation for the treatment of blemished skin and acne or a preparation for the treatment of foot and/or skin fungus.Type: ApplicationFiled: February 18, 2009Publication date: December 9, 2010Applicant: AIR LIQUIDE SANTE (INTERNATIONAL)Inventors: Wolfgang Beilfuss, Klaus Weber, Ralf Gradtke, Sabine Herwig
-
Publication number: 20100298251Abstract: The present invention relates to Momordicae semen extract having wound-healing efficiencies. In particular, the present invention relates to a wound-healing topical transdermal agent comprising an active ingredient of Momordicae semen extract, which is capable of reducing the time required for the closure and treatment of wounds as confirmed in skin-wound induced animal model.Type: ApplicationFiled: October 21, 2008Publication date: November 25, 2010Inventors: Bongcheol Kim, Joo-Hyun Kim, Se-Jun Yun, Gi-Uk Jang, Sungsoo Pyo
-
Publication number: 20100298249Abstract: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery.Type: ApplicationFiled: April 22, 2008Publication date: November 25, 2010Inventors: Marc Moutet, Jean-Claude Yadan
-
Publication number: 20100298250Abstract: Methods and compositions for treating at least one symptom of a viral infection, said method of treatment comprising administering to a subject with a least one symptom of a viral infection an effective dosage unit of a composition comprising pomegranate extract. The compositions comprise pomegranate extract comprising polyphenols. The composition is produced by a process comprising providing one or more pomegranate solids selected from the group consisting of a pericarp, inner membrane and seeds, creating a mixture comprising said one or more pomegranate solids in an aqueous solution, heating said mixture to a temperature that permits enzyme catalysis of said pomegranate solids, and removing residual insoluble solid materials from said mixture to provide said pomegranate extract. Compositions containing the extract may be used as a food product, beverage, pharmaceutical preparations, nutritional supplements, vitamin supplements, food additives, and food supplements.Type: ApplicationFiled: March 23, 2010Publication date: November 25, 2010Inventors: Mohammad MADJID, Harley R. Liker
-
Patent number: 7811997Abstract: The invention relates to a composition containing total triterpenoid sapogenins extracted from bamboo, the preparation method and use thereof. These total triterpenoid sapogenins are extracted from many parts of bamboo such as bamboo shavings in Gramineae by CO2 Supercritical Fluid Extraction technique. In the extract, the content of total triterpenoid sapogenins is 10-90%, while the contents of friedelin and lupenone are 5-35% and 1-10%, respectively. The extract in the invention has good physiological and pharmacological activities such as anti-free radical, anti-oxidation, anti-tumor and anti-hypertension. It can be used in medicines or functional foods for the treatment or prevention of cardiovascular and cerebrovascular diseases and tumor. It is also useful in cosmetics field.Type: GrantFiled: April 28, 2003Date of Patent: October 12, 2010Inventors: Ying Zhang, Xiaoqin Wu, Zhuoyu Yu, Yunlong Zhu, Lingen Chen, Shenggen Lou
-
Publication number: 20100256080Abstract: The present invention relates to a compound The instant invention relates to a compound of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B), wherein R? represents and R? represents hydrogen, hydroxy, C1-C7alkoxy, C1-C8-alkanoyloxy, or R5R4N—CO—O—, where R4 and R5 independently are C1-C7alkyl or phenyl which is unsubstituted or substituted by a substitutent selected from C1-C7alkyl, C1-C7alkoxy, halogen and trifluoromethyl and where R4 additionally is hydrogen; or R4 and R5 together represent C3-C6alkylene; in free form or in form of a pharmaceutically acceptable acid addition salt. Compounds of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B) inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.Type: ApplicationFiled: November 25, 2008Publication date: October 7, 2010Inventors: Ulrich Hassiepen, Matthias Kittelmann
-
Publication number: 20100227830Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.Type: ApplicationFiled: August 3, 2007Publication date: September 9, 2010Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl
-
Publication number: 20100222291Abstract: A method for producing an encapsulated medicinal form of a combination of phospholipid and glycyrrhizic acid or a pharmaceutically acceptable salt thereof, said method comprising mixing a solution of phospholipid in an organic solvent with glycyrrhizic acid or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier substance or additive, granulating the resultant mixture, and encapsulating the resultant product, for example after grinding with a pharmaceutically acceptable carrier substance or additive. Products obtained by this method form a further aspect of the invention, and are useful in the treatment or prevention of diseases associated with liver disorders.Type: ApplicationFiled: August 11, 2006Publication date: September 2, 2010Inventors: Mariya Kirillovna Guseva, Vasiliy Fedorovich Uchaikin, Elena Georgievna Tikhonova, Olga Mikhailovna Ipatova
-
Publication number: 20100221351Abstract: In accordance with certain embodiments of the present disclosure, A method for intracellular delivery of cytotoxin in combination with cyoablation is provided. The method includes encapsulation of one or more cytotoxins in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule whereby the one or more cytotoxins are sucked into or diffuse into the nanocapsule. The temperature of the nanocapsule is increased and the nanocapsule is delivered into a cell. Cryoablation is performed in proximity to the cell resulting in the release of the one or more cytotoxins from the nanocapsule into the cell.Type: ApplicationFiled: March 1, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF SOUTH CAROLINAInventor: Xiaoming He
-
Patent number: 7776832Abstract: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.Type: GrantFiled: April 21, 2006Date of Patent: August 17, 2010Assignee: Gem Pharmaceuticals, LLCInventors: Richard D. Olson, Gerald M. Walsh
-
Publication number: 20100204169Abstract: This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder.Type: ApplicationFiled: March 1, 2010Publication date: August 12, 2010Applicant: PACIFIC ARROW LIMITEDInventors: Pui-Kwong CHAN, May Sung MAK, Yun WANG
-
Patent number: 7772192Abstract: Compositions and methods for treatment of disease with acetylated disaccharides and analogs thereof are provided.Type: GrantFiled: June 1, 2004Date of Patent: August 10, 2010Assignee: The Regents of the University of CaliforniaInventor: Jeffrey D. Esko
-
Patent number: 7767200Abstract: Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.Type: GrantFiled: July 12, 2006Date of Patent: August 3, 2010Assignee: Wellstat Biologics CorporationInventors: Robert M. Lorence, Michael S. Roberts
-
Publication number: 20100189824Abstract: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.Type: ApplicationFiled: January 15, 2010Publication date: July 29, 2010Inventors: CHARLES J. ARNTZEN, Mary E. Blake, Jordan U. Gutterman, Joseph J. Hoffmann, Gamini S. Jayatilake, David T. Bailey
-
Publication number: 20100179100Abstract: A method for producing a pharmaceutical composition comprising a combination of phospholipid and glycyrrhizic acid or a pharmaceutically acceptable salt thereof, which composition is hydratable to produce an injectable medicinal form, said method comprising subjecting a mixture of phospholipid and an aqueous solution of glycyrrhizic acid or a pharmaceutically acceptable salt thereof and a carbohydrate to homogenization, for example at 800-1200 bar pressure at a temperature of less than 90° C., and subjecting the product of the homogenization to a sublimation drying step to produce said composition. Compositions obtainable using this method, and hydrated forms of these ready for administration by injection form further aspects of the invention.Type: ApplicationFiled: August 11, 2006Publication date: July 15, 2010Inventors: Mariya Kirillovna Guseva, Vasiliy Fedorovich Uchaikin, Elena Georgievna Tikhonova, Olga Mikhailovna Ipatova
-
Publication number: 20100173861Abstract: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use.Type: ApplicationFiled: January 16, 2008Publication date: July 8, 2010Inventors: Ru Chih C. Huang, Ibrahim S. Abd-Elazem
-
Patent number: 7745235Abstract: A semiconductor sensor is disclosed that includes a substrate including at least a semiconductor layer. The substrate includes a weight arranging part in the vicinity of the center of the substrate, a flexible part around the weight arranging part, and supporting parts provided around the flexible part. The semiconductor sensor further includes a weight arranged on the weight arranging part. The weight is made of a material different from that of the weight arranging part and the flexible parts.Type: GrantFiled: June 5, 2008Date of Patent: June 29, 2010Assignee: Ricoh Company, Ltd.Inventor: Kazunari Kimino
-
Publication number: 20100152124Abstract: This invention relates to a use of hederagenin 3-O-?-L-rhamnopyranosyl((1?2)-[?-D-glucopyranosyl(1?4)]-?-L-arabinopyranoside or a Pulsatillae radix extract containing the same as a therapeutic agent for solid tumors. Also, this invention relates to a method of preparing a therapeutic agent for solid tumors by using hederagenin 3-O-?-L-rhamnopyranosyl(1?2)-[?-D-glucopyranosyl(1?4)]-?-L-arabinopyranoside, or a method of treating a subject suffering from solid tumors, comprising administering to the subject a therapeutically effective dose of hederagenin 3-O-?-L-rhamnopyranosyl(1?2)-[?-D-glucopyranosyl(1?4)]-?-L-arabinopyranoside.Type: ApplicationFiled: February 22, 2010Publication date: June 17, 2010Inventors: Song-Bae Kim, Byung-Zun Ahn, Yong Kim
-
Publication number: 20100143296Abstract: The present invention relates to new podophyllotoxin inhibitors of topoisomerase II, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 10, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Patent number: 7732582Abstract: A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The dicarboxylic acid compound has significantly improved water-solubility compared with the raw material antibiotics, whist maintaining the specific microorganism binding property.Type: GrantFiled: September 5, 2005Date of Patent: June 8, 2010Assignee: FUJIFILM CorporationInventors: Toshikazu Oki, Yasuhiro Igarashi, Tamotsu Furumai
-
Publication number: 20100119591Abstract: The present invention relates to the use of lipid containing particles, such as liposomes, iscom and/or iscom matrix and posintros, comprising at least one lipid and at least one saponin for the preparation of a pharmaceutical for the treatment of cancer. The saponins are preferably from Quillaja Saponaria Molin. Further, the particles are also delivery systems for one or several compounds for cancer treatment with complementary mechanisms. More, the invention discloses kit of parts comprising at least two parts, wherein one part comprising at least one saponin fraction which is hydrophobic having a killing effect on cancer cell; and the other part comprising at least one saponin fraction which is comparatively hydrophilic, stimulating and modulating the immune response.Type: ApplicationFiled: November 20, 2007Publication date: May 13, 2010Inventors: Kefei Hu, Bror Morein
-
Patent number: 7683163Abstract: The present invention relates to colchicine derivatives, in particular to the 3-demethyl and 3-demethylthio-colchicine of the general formula (I) in which X is oxygen or sulfur, a method for the preparation thereof and pharmaceutical compositions containing them. The compounds of formula (I) have muscle relaxing, anti-inflammatory and anti-gout activity.Type: GrantFiled: May 26, 2004Date of Patent: March 23, 2010Assignee: Indena S.p.A.Inventors: Ezio Bombardelli, Gabriele Fontana
-
Publication number: 20100004190Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.Type: ApplicationFiled: August 14, 2009Publication date: January 7, 2010Applicant: PACIFIC ARROW LIMITEDInventors: Pui-Kwong CHAN, May Sung MAK
-
Publication number: 20090318376Abstract: The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors of the binding between caspase3 and xIAP on a biochip for detecting caspase3:xIAP interaction, and selecting a candidate substance inhibiting the binding of caspase3 to xIAP as an anticancer substance, and an anticancer agent inhibiting caspase3:xIAP binding, which is screened by the above method. According to present invention, it is possible to develop a target-oriented anticancer agent focused on xIAP and caspase3, apoptosis-related proteins and thus it can be applied to tailored medication and combination therapy.Type: ApplicationFiled: June 12, 2006Publication date: December 24, 2009Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Bong Hyun Chung, Kwang-Hee Son, Moonil Kim, Kyoungsook Park, Byoung-Mog Kwon, Hyun Jung Junn, Dong Cho Han, Sun-Hee Jeon
-
Publication number: 20090318377Abstract: A cholesterol-lowering preparation comprising medicagenic acid saponin is disclosed. The amount of medicagenic acid saponin in the preparation is greater than 50% by weight to produce the cholesterol-lowering effect in an animal. A method of purifying a preparation of at least 30% medicagenic acid saponin is also disclosed. The preparation may be purified from alfalfa plants and used as a treatment for lowering cholesterol and triglycerides in an animal, in particular a human.Type: ApplicationFiled: July 13, 2007Publication date: December 24, 2009Applicant: MEDICAGO INC.Inventors: Louis-Philippe Vezina, Nathalie Landry, Joelle Pelletier, Sylvain Savard
-
Publication number: 20090291905Abstract: The present invention concerns the use of tricyclic terpenes chosen from the group consisting of fusicoccin, ophyobolins or cotylenins for the therapy and diagnosis of coagulation-correlated pathologies such as Bernard-Soulier syndrome (BSS), von Willebrand disease (vWD), Glanzmann's thrombasthenia or thrombocytopenia.Type: ApplicationFiled: May 23, 2008Publication date: November 26, 2009Applicant: UNIVERSITA' DEGLI STUDI DI ROMA "TOR VEGATA"Inventors: Patrizia ADUCCI, Lorenzo Camoni, Cristina Di Lucente, Sabina Visconti
-
Patent number: 7622450Abstract: The present invention relates to novel flavone C-glycoside derivatives or salts thereof, especially those showing an anti-allergic effect, and compositions containing them. Recently, cases of allergic diseases, especially pollenosis and atopic dermatitis have increased to such a degree that they have become a social problem. Flavones and their glycosides have been reported to have the effect of inhibiting histamine release from mast cells or an immunosuppressive effect and expected for application as allergy therapies. However, most flavones exhibit their effects only at high doses, so that effective compounds at lower doses are highly desired. The present invention provides novel components capable of treating allergic diseases at low doses and compositions containing them.Type: GrantFiled: July 3, 2003Date of Patent: November 24, 2009Assignee: Suntory Holdings LimitedInventors: Yoshiyuki Ishikura, Kuniro Tsuji, Haruo Nukaya
-
Patent number: 7618946Abstract: Various compounds obtained from plants of the Barringtonia species which are derived from Barringtoside A and Barringtoside C as precursor compounds which especially have an arabinopyranosyl substituent at the 21 position which may optionally be further substituted with benzoyl, dibenzoyl, methyl butanoyl, methyl butyryl or tigloyl at the 3 or 4 positions. Alternatively at the 21 position there is provided tigloyl, benzoyl or dibenzoyl substituents.Type: GrantFiled: November 26, 2004Date of Patent: November 17, 2009Assignees: Griffith University, Jarlmadangah Buru Aboriginal CorporationInventors: Ronald Quinn, Clive Mills
-
Publication number: 20090263512Abstract: This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder.Type: ApplicationFiled: February 25, 2009Publication date: October 22, 2009Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Patent number: 7605135Abstract: The present invention relates to a pharmaceutical composition useful for the treatment of diseases associated with viruses of the order Nidovirales of the family Coronaviradae, such as Severe Acute Respiratory Syndrome (SARS) viruses in humans and other animals. In particular, this invention relates to a naturally occurring compound, namely, baicalin, extracted and purified from the Chinese medicinal plant Scutellaria baicalensis Georgi (Chinese name: Huang Qin), that exhibits potent antiviral activity against members of the order Nidovirales of the family Coronaviradae that infects humans and other animals; in particular, SARS viruses in humans (“hSARS virus”). The invention also relates to a therapeutic method, using pharmaceutical compositions comprising baicalin compounds, for the treatment, amelioration, management or prevention of diseases associated with members of the order Nidovirales of the family Coronaviradae, such as hSARS.Type: GrantFiled: November 8, 2004Date of Patent: October 20, 2009Assignee: The University of Hong KongInventors: Kwok Yung Yuen, Feng Chen, Kwok Hung Chan, Yi Tsun Kao, Yi Guan, Leo Lit Man Poon, JSM Peiris
-
Publication number: 20090215708Abstract: Methods of treating a subject for sexual dysfunction are provided. Aspects of the methods include administering to the subject an effective amount of a proton pump agonist. Aspects of the invention further include proton pump agonist compositions employed in methods of the invention.Type: ApplicationFiled: February 18, 2009Publication date: August 27, 2009Inventor: Bradley Stuart Galer
-
Publication number: 20090203634Abstract: Amooranin (AMR) has been found to cause tumor cell death through G2/M cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds, including AMR analogs, can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.Type: ApplicationFiled: April 14, 2006Publication date: August 13, 2009Applicant: Variety Children's Hospital d/b/a Miami Children's HospitalInventors: Cheppail Ramachandran, P.K. Raveendran Nair, Steven J. Melnick
-
Publication number: 20090175938Abstract: This invention is a novel controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration with anti-inflammatory, analgesic, myorelaxant activity and methods of its manufacture. The pharmaceutical composition of the present invention is administered orally in tablet, multilayer tablet, multicoated tablet and capsule form.Type: ApplicationFiled: December 24, 2008Publication date: July 9, 2009Applicant: SANOVEL ILAC SANAYI VE TICARET A.S.Inventors: Umit Cifter, Ali Turkyilmaz, Hasan Ali Turp
-
Patent number: 7557091Abstract: The invention relates to the novel antibiotic HKI10311129 which has a molecular weight of 1113 and the summation formula C56H75NO22. The invention also relates to a method for producing said antibiotic using the microorganism Streptomyces spec. DSM 13059, and to the use thereof as an antibacterial substance which is especially effective against infections with Gram positive bacteria, especially antibiotic-resistant germs.Type: GrantFiled: February 2, 2005Date of Patent: July 7, 2009Assignee: Leibniz-Institut fuer Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knoell-InstitutInventors: Ute Moellmann, Kerstin Herold, Martin Roth, Ingrid Groth, Friedrich Gollmick, Karin Brigitte Charlotte Graefe, legal representative, Andrea Graefe, legal representative, Susanna Graefe, legal representative, Udo Graefe
-
Publication number: 20090156515Abstract: This invention provides composition comprising a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, comprising at least two side groups selected from the group consisting of: angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin backbone. This invention provides a composition for inhibiting tumor cell growth, comprising an appropriate amount of a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, wherein the triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin comprises any two side groups selected from the group consisting of: angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin backbone.Type: ApplicationFiled: December 29, 2008Publication date: June 18, 2009Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Patent number: 7544668Abstract: Two hitherto unreported novel triterpene saponins were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of the triterpene saponin fraction have been elucidated to possess anti-inflammatory and analgesic activity. These two novel triterpene saponins and the triterpene saponin fraction may be used as pharmaceutical compositions in humans and mammals in need of such treatment.Type: GrantFiled: November 17, 2006Date of Patent: June 9, 2009Assignee: Hong Kong Baptist UniversityInventors: Liang Liu, Jing Rong Wang, Hua Zhou, Zhi Hong Jiang
-
Patent number: 7541342Abstract: Compounds for the inducing apoptosis in cancer cells are described. The described compounds induce the translocation of protein kinase C-? to the mitochondria and the phosphorylation of mitochondrial phospholipid scramblase 3. The compounds also provide cardioprotection through the translocation and activation of protein kinase C-? in cardiomyocytes, thereby inhibiting apoptosis in carciomyocytes.Type: GrantFiled: March 6, 2006Date of Patent: June 2, 2009Assignee: University of Tennessee Research FoundationInventors: Leonard Lothstein, Mervyn Israel, Trevor Sweatman, Polly A. Hofmann
-
Patent number: 7534768Abstract: The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infections.Type: GrantFiled: December 17, 2004Date of Patent: May 19, 2009Assignee: Henderson Morely Research and Development Ltd.Inventor: Christopher Edward Hartley
-
Patent number: 7531521Abstract: The present invention provides a novel method for inhibiting sugar-induced weight gain resulting from fructose and glucose driven lipogenesis. The method for inhibiting sugar-induced weight gain is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants to a host in need thereof. The present also includes novel methods for the prevention and treatment of diseases and conditions resulting from high carbohydrate ingestion. The method for preventing and treating these sugar-induced diseases and conditions is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants and a pharmaceutically acceptable carrier.Type: GrantFiled: February 24, 2004Date of Patent: May 12, 2009Assignee: Unigen Pharmaceuticals, Inc.Inventors: Bruce P. Burnett, Qi Jia
-
Publication number: 20090118204Abstract: Disclosed are compositions related to water soluble selective COX-2 inhibitors and methods of using the inhibitors (including Esculentoside A and derivatives thereof).Type: ApplicationFiled: November 18, 2005Publication date: May 7, 2009Applicant: UNIVERSITY OF ROCHESTERInventors: Paul OKUNIEFF, Lurong ZHANG, Zhenyu XIAO
-
Patent number: 7524824Abstract: This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating breast, leukocyte, liver, ovarian, bladder, prostate, bone or brain cancer. This invention provides compounds comprising at least one sugar, a triterpene, such as Sapogenin, and at least one side chains at Carbon 21 and 22, such as Angeloyl groups. The compounds of the present have various pharmaceutical and therapeutic applications, including treating breast, leukocyte, liver, ovarian, bladder, prostate, bone or brain cancer.Type: GrantFiled: February 14, 2005Date of Patent: April 28, 2009Assignee: Pacific Arrow LimitedInventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Patent number: 7514412Abstract: Novel compounds such as compounds designated herein as Y or Y3, Y1, Y2, Y8, Y9 and Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapindaceae family, such as Xanthoceras sorbifolia, or other natural sources or products. The compounds of the present invention may also be synthesized chemically.Type: GrantFiled: April 27, 2005Date of Patent: April 7, 2009Assignee: Pacific Arrow LimitedInventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Publication number: 20090088396Abstract: A combination of active substances for cosmetic preparations contains hyaluronic acid and at least one of its derivatives. At least 10 percent by weight is used in long-chain form with a molecular weight of at least 1,000,000 daltons. At least 2 percent by weight is used in short-chain form with a molecular weight not more than 200,000 daltons.Type: ApplicationFiled: December 4, 2008Publication date: April 2, 2009Inventor: Marcus Asam
-
Publication number: 20090074708Abstract: A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, ?-naphthoflavone, ?-naphthoflavone, hesperetin, terpineol, (+)-limonene, ?-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof.Type: ApplicationFiled: November 28, 2008Publication date: March 19, 2009Inventors: Yoa-Pu Hu Oliver, Cheng-Huei Hsiong, Mei-Ting Wang, Li-Heng Pao
-
Publication number: 20090075919Abstract: The present invention provides a composition for use in treating or preventing neoplasia, comprising an effective actein. The present invention also provides a composition for use in treating or preventing neoplasia, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh. The present invention further provides a combination of anti-neoplastic agents, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh and an effective anti-neoplastic amount of at least one additional chemopreventive or chemotherapeutic agent. Methods for treating and preventing neoplasia are also provided.Type: ApplicationFiled: August 4, 2008Publication date: March 19, 2009Inventors: Linda Saxe Einbond, I. Bernard Weinstein
-
Publication number: 20090028914Abstract: Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is an absorbable esophageal or tracheal stent. In some embodiments, the device is a vascular stent. Wound closure devices are also provided herein, including a substrate and a collagen inhibitor on or in the substrate. Also provided are surgical packings, including a substrate and a collagen inhibitor on or in the substrate. A barrier material for preventing adhesions in a subject is further provided, including a preformed or in situ formable barrier substrate and a collagen inhibitor on or in the substrate. An ointment comprising a collagen inhibitor is further provided. Kits comprising the coated substrates are also provided.Type: ApplicationFiled: May 30, 2008Publication date: January 29, 2009Applicant: Wake Forest University Health ScienceInventors: Christopher A. Sullivan, Steve J. Hodges